The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...
In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...
Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback